Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities researchers at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Nkarta in a research note issued to investors on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings per share of ($1.77) for the year. The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Nkarta's Q4 2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($2.10) EPS and FY2028 earnings at ($1.86) EPS.
A number of other research firms also recently weighed in on NKTX. Needham & Company LLC reduced their price target on shares of Nkarta from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Friday, November 8th. HC Wainwright cut their target price on shares of Nkarta from $22.00 to $18.00 and set a "buy" rating on the stock in a research report on Monday, November 11th. Finally, Mizuho lowered their price target on shares of Nkarta from $20.00 to $16.00 and set an "outperform" rating for the company in a report on Thursday, November 21st. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $15.00.
Get Our Latest Analysis on Nkarta
Nkarta Price Performance
NASDAQ:NKTX traded down $0.14 during trading hours on Monday, hitting $2.15. The company's stock had a trading volume of 874,663 shares, compared to its average volume of 1,028,923. Nkarta has a twelve month low of $1.96 and a twelve month high of $16.24. The stock has a fifty day simple moving average of $2.33 and a 200-day simple moving average of $3.52. The company has a market capitalization of $151.73 million, a P/E ratio of -1.14 and a beta of 0.85.
Insider Buying and Selling at Nkarta
In related news, CEO Paul J. Hastings sold 17,378 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total value of $38,231.60. Following the transaction, the chief executive officer now directly owns 319,859 shares in the company, valued at $703,689.80. This trade represents a 5.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 8.70% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of NKTX. The Manufacturers Life Insurance Company increased its position in shares of Nkarta by 92.9% during the second quarter. The Manufacturers Life Insurance Company now owns 20,710 shares of the company's stock worth $122,000 after acquiring an additional 9,975 shares in the last quarter. SG Americas Securities LLC bought a new stake in Nkarta during the 3rd quarter worth approximately $93,000. Intech Investment Management LLC bought a new stake in Nkarta during the 3rd quarter worth approximately $74,000. FMR LLC raised its stake in shares of Nkarta by 97.1% in the third quarter. FMR LLC now owns 133,149 shares of the company's stock worth $602,000 after purchasing an additional 65,600 shares during the last quarter. Finally, Wasatch Advisors LP lifted its holdings in shares of Nkarta by 31.7% in the third quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company's stock valued at $8,293,000 after purchasing an additional 442,125 shares in the last quarter. Institutional investors and hedge funds own 80.54% of the company's stock.
About Nkarta
(
Get Free Report)
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Featured Stories
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
